menu
    • menu
    [{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Eversana","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuroscience Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Partnership","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"OWP Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"OWP Pharmaceuticals \/ EVERSANA","highestDevelopmentStatusID":"5","companyTruncated":"OWP Pharma.."},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neuraxpharm Reinforces Presence in Poland with The Acquisition of Glenmark\u2019s CNS Product Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Lamotrigine","moa":"Sodium channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Neuraxpharm Group","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark P.."}]

    Find Clinical Drug Pipeline Developments & Deals for Epitec

    Menu

    Epitec

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OWP Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            OWP Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Eversana

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuro...

                            Details : Under the partnership OWP will launch and commercialize its oral liquid formulations for neuroscience disorders. OWP has also received IND for Lamotrigine in multiple therapies for epilepsy, schizophrenia, bipolar disorder, major depressive, anxiety diso...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 05, 2022

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Eversana

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Glenmark Pharmaceuticals

                            India arrow
                            Formnext Forum
                            Not Confirmed

                            Glenmark Pharmaceuticals

                            India arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm Reinforces Presence in Poland with The Acquisition of Glenmark’s CNS Product Portfolio

                            Details : Aquistion covers the lead products include the branded generics Cital® and Lamotrix® (lamotrigine), both relevant brands in their respective markets. With branded generics commanding the dominant share of market, Poland has the highest penetration of g...

                            Brand Name : Lamotrix

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 25, 2020

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            Close
                            4